Related Experiment Video
Updated: May 5, 2026
Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
The progress and future of the treatment of Candida albicans infections based on nanotechnology
Yang Gao1, Qinyan Cao1, Yuyang Xiao1
1International Center for Synthetic Biology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Abstract:
Systemic infection with Candida albicans poses a significant risk for people with weakened immune systems and carries a mortality rate of up to 60%. However, current therapeutic options have several limitations, including increasing drug tolerance, notable off-target effects, and severe adverse reactions. Over the past four decades, the progress in developing drugs to treat Candida albicans infections has been sluggish. This comprehensive review addresses the limitations of existing drugs and summarizes the efforts made toward redesigning and innovating existing or novel drugs through nanotechnology. The discussion explores the potential applications of nanomedicine in Candida albicans infections from four perspectives: nano-preparations for anti-biofilm therapy, innovative formulations of "old drugs" targeting the cell membrane and cell wall, reverse drug resistance therapy targeting subcellular organelles, and virulence deprivation therapy leveraging the unique polymorphism of Candida albicans. These therapeutic approaches are promising to address the above challenges and enhance the efficiency of drug development for Candida albicans infections. By harnessing nano-preparation technology to transform existing and preclinical drugs, novel therapeutic targets will be uncovered, providing effective solutions and broader horizons to improve patient survival rates.
Insights
Nanotechnology offers innovative solutions for treating Candida albicans infections, addressing limitations of current therapies. This approach enhances drug development and improves patient survival rates for systemic fungal infections.
Area of Science:
- Mycology
- Nanomedicine
- Infectious Diseases
Background:
- Systemic Candida albicans infections are life-threatening, especially in immunocompromised individuals, with high mortality rates.
- Existing antifungal drugs face challenges like increasing drug resistance, off-target effects, and adverse reactions.
- Therapeutic advancements for Candida albicans infections have been limited over the last four decades.
Purpose of the Study:
- To review the limitations of current Candida albicans treatments.
- To summarize nanomedicine-based strategies for developing novel antifungal therapies.
- To explore innovative drug redesign and development using nanotechnology.
Main Methods:
- Review of existing literature on Candida albicans infections and nanotechnology applications.
- Analysis of nanomedicine approaches including anti-biofilm therapy, novel drug formulations, reverse drug resistance, and virulence deprivation.
- Exploration of nanotechnology's role in targeting Candida albicans cell structures and virulence factors.
Main Results:
- Nanotechnology offers four key therapeutic avenues: nano-preparations for anti-biofilm therapy, innovative "old drug" formulations, reverse drug resistance targeting organelles, and virulence deprivation.
- These nanomedicine approaches address limitations of current therapies, including drug resistance and adverse effects.
- Harnessing nano-preparation technology can uncover novel therapeutic targets and improve drug efficacy.
Conclusions:
- Nanomedicine presents promising strategies to overcome challenges in treating Candida albicans infections.
- Innovative drug development through nanotechnology can enhance treatment efficiency and patient survival.
- Further research into nano-preparation technologies is crucial for effective antifungal solutions.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:24Microbial Corrosion
01:15Antifungal Agents